Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990;30(Suppl 1):99S–106S. doi: 10.1111/j.1365-2125.1990.tb05475.x

The role of platelet activating factor in allergic respiratory disease

C P Page
PMCID: PMC1368105  PMID: 2268512

Abstract

1 Platelet activating factor (PAF) is an ether-linked phospholipid capable of eliciting many of the factors of the allergic response including bronchoconstriction, mucosal oedema, eosinophil infiltration and bronchial hyperresponsiveness.

2 A wide range of selective PAF receptor antagonists have now been described which have been reported to reduce many aspects of allergen-induced inflammatory responses in experimental animals.

3 Early clinical studies have indicated that some of these drugs are also effective PAF antagonists in man, but no controlled studies have been reported using these compounds in patients with allergic asthma.

4 The gingkolide mixture BN 52063 has recently been reported to inhibit allergen-induced cutaneous inflammation in man; a response which has certain pathological similarities to allergen-induced late-onset airways obstruction in the lung.

5 Therefore, drugs antagonizing the actions of PAF may well lead to a better understanding of and may be a novel therapeutic approach for allergic respiratory disorders.

Keywords: platelet activating factor, BN 52063

Full text

PDF
99S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Advenier C., Devillier P., Matran R., Naline E. Influence of epithelium on the responsiveness of guinea-pig isolated trachea to adenosine. Br J Pharmacol. 1988 Feb;93(2):295–302. doi: 10.1111/j.1476-5381.1988.tb11434.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Arnout J., van Hecken A., De Lepeleire I., Miyamoto Y., Holmes I., De Schepper P., Vermylen J. Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man. Br J Clin Pharmacol. 1988 Apr;25(4):445–451. doi: 10.1111/j.1365-2125.1988.tb03328.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barnes P. J., Grandordy B. M., Page C. P., Rhoden K. J., Robertson D. N. The effect of platelet activating factor on pulmonary beta-adrenoceptors. Br J Pharmacol. 1987 Apr;90(4):709–715. doi: 10.1111/j.1476-5381.1987.tb11224.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beasley R., Roche W. R., Roberts J. A., Holgate S. T. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am Rev Respir Dis. 1989 Mar;139(3):806–817. doi: 10.1164/ajrccm/139.3.806. [DOI] [PubMed] [Google Scholar]
  5. Black J. W., Shankley N. P. The isolated stomach preparation of the mouse: a physiological unit for pharmacological analysis. Br J Pharmacol. 1985 Nov;86(3):571–579. doi: 10.1111/j.1476-5381.1985.tb08933.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Braquet P., Touqui L., Shen T. Y., Vargaftig B. B. Perspectives in platelet-activating factor research. Pharmacol Rev. 1987 Jun;39(2):97–145. [PubMed] [Google Scholar]
  7. Bruijnzeel P. L., Kok P. T., Hamelink M. L., Kijne A. M., Verhagen J. Platelet-activating factor induces leukotriene C4 synthesis by purified human eosinophils. Prostaglandins. 1987 Aug;34(2):205–214. doi: 10.1016/0090-6980(87)90244-9. [DOI] [PubMed] [Google Scholar]
  8. Casals-Stenzel J., Weber K. H. Triazolodiazepines: dissociation of their Paf (platelet activating factor) antagonistic and CNS activity. Br J Pharmacol. 1987 Jan;90(1):139–146. doi: 10.1111/j.1476-5381.1987.tb16833.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Chung K. F., Dent G., Barnes P. J. Effects of salbutamol on bronchoconstriction, bronchial hyperresponsiveness, and leucocyte responses induced by platelet activating factor in man. Thorax. 1989 Feb;44(2):102–107. doi: 10.1136/thx.44.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Coyle A. J., Page C. P., Atkinson L., Sjoerdsma K., Touvay C., Metzger W. J. Modification of allergen-induced airway obstruction and airway hyperresponsiveness in an allergic rabbit model by the selective platelet-activating factor antagonist, BN 52021. J Allergy Clin Immunol. 1989 Dec;84(6 Pt 1):960–967. doi: 10.1016/0091-6749(89)90395-3. [DOI] [PubMed] [Google Scholar]
  11. Coyle A. J., Urwin S. C., Page C. P., Touvay C., Villain B., Braquet P. The effect of the selective PAF antagonist BN 52021 on PAF- and antigen-induced bronchial hyper-reactivity and eosinophil accumulation. Eur J Pharmacol. 1988 Mar 22;148(1):51–58. doi: 10.1016/0014-2999(88)90453-0. [DOI] [PubMed] [Google Scholar]
  12. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., Ball M., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet. 1989 Apr 29;1(8644):917–922. doi: 10.1016/s0140-6736(89)92505-1. [DOI] [PubMed] [Google Scholar]
  13. Cuss F. M., Dixon C. M., Barnes P. J. Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet. 1986 Jul 26;2(8500):189–192. doi: 10.1016/s0140-6736(86)92489-x. [DOI] [PubMed] [Google Scholar]
  14. DUNNILL M. S. The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol. 1960 Jan;13:27–33. doi: 10.1136/jcp.13.1.27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. De Monchy J. G., Kauffman H. F., Venge P., Koëter G. H., Jansen H. M., Sluiter H. J., De Vries K. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am Rev Respir Dis. 1985 Mar;131(3):373–376. doi: 10.1164/arrd.1985.131.3.373. [DOI] [PubMed] [Google Scholar]
  16. Devillier P., Advenier C., Drapeau G., Marsac J., Regoli D. Comparison of the effects of epithelium removal and of an enkephalinase inhibitor on the neurokinin-induced contractions of guinea-pig isolated trachea. Br J Pharmacol. 1988 Jul;94(3):675–684. doi: 10.1111/j.1476-5381.1988.tb11575.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Erjefält I., Persson C. G. Inflammatory passage of plasma macromolecules into airway wall and lumen. Pulm Pharmacol. 1989;2(2):93–102. doi: 10.1016/0952-0600(89)90030-6. [DOI] [PubMed] [Google Scholar]
  18. Evans T. W., Chung K. F., Rogers D. F., Barnes P. J. Effect of platelet-activating factor on airway vascular permeability: possible mechanisms. J Appl Physiol (1985) 1987 Aug;63(2):479–484. doi: 10.1152/jappl.1987.63.2.479. [DOI] [PubMed] [Google Scholar]
  19. Fernandes L. B., Paterson J. W., Goldie R. G. Co-axial bioassay of a smooth muscle relaxant factor released from guinea-pig tracheal epithelium. Br J Pharmacol. 1989 Jan;96(1):117–124. doi: 10.1111/j.1476-5381.1989.tb11791.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Folkerts G., Engels F., Nijkamp F. P. Endotoxin-induced hyperreactivity of the guinea-pig isolated trachea coincides with decreased prostaglandin E2 production by the epithelial layer. Br J Pharmacol. 1989 Feb;96(2):388–394. doi: 10.1111/j.1476-5381.1989.tb11829.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Frigas E., Gleich G. J. The eosinophil and the pathophysiology of asthma. J Allergy Clin Immunol. 1986 Apr;77(4):527–537. doi: 10.1016/0091-6749(86)90341-6. [DOI] [PubMed] [Google Scholar]
  22. Frigas E., Loegering D. A., Gleich G. J. Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest. 1980 Jan;42(1):35–43. [PubMed] [Google Scholar]
  23. Fukuda T., Gleich G. J. Heterogeneity of human eosinophils. J Allergy Clin Immunol. 1989 Feb;83(2 Pt 1):369–373. doi: 10.1016/0091-6749(89)90120-6. [DOI] [PubMed] [Google Scholar]
  24. Gibson P. G., Dolovich J., Denburg J., Ramsdale E. H., Hargreave F. E. Chronic cough: eosinophilic bronchitis without asthma. Lancet. 1989 Jun 17;1(8651):1346–1348. doi: 10.1016/s0140-6736(89)92801-8. [DOI] [PubMed] [Google Scholar]
  25. Henocq E., Vargaftig B. B. Skin eosinophilia in atopic patients. J Allergy Clin Immunol. 1988 Apr;81(4):691–695. doi: 10.1016/0091-6749(88)91040-8. [DOI] [PubMed] [Google Scholar]
  26. Jacoby D. B., Ueki I. F., Widdicombe J. H., Loegering D. A., Gleich G. J., Nadel J. A. Effect of human eosinophil major basic protein on ion transport in dog tracheal epithelium. Am Rev Respir Dis. 1988 Jan;137(1):13–16. doi: 10.1164/ajrccm/137.1.13. [DOI] [PubMed] [Google Scholar]
  27. Kerrebijn K. F., van Essen-Zandvliet E. E., Neijens H. J. Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma. J Allergy Clin Immunol. 1987 Apr;79(4):653–659. doi: 10.1016/s0091-6749(87)80163-x. [DOI] [PubMed] [Google Scholar]
  28. Kimani G., Tonnesen M. G., Henson P. M. Stimulation of eosinophil adherence to human vascular endothelial cells in vitro by platelet-activating factor. J Immunol. 1988 May 1;140(9):3161–3166. [PubMed] [Google Scholar]
  29. Kloprogge E., de Leeuw A. J., de Monchy J. G., Kauffman H. F. Hypodense eosinophilic granulocytes in normal individuals and patients with asthma: generation of hypodense cell populations in vitro. J Allergy Clin Immunol. 1989 Feb;83(2 Pt 1):393–400. doi: 10.1016/0091-6749(89)90124-3. [DOI] [PubMed] [Google Scholar]
  30. Kornecki E., Ehrlich Y. H., Lenox R. H. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. Science. 1984 Dec 21;226(4681):1454–1456. doi: 10.1126/science.6150550. [DOI] [PubMed] [Google Scholar]
  31. Kraan J., Koëter G. H., vd Mark T. W., Sluiter H. J., de Vries K. Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline. J Allergy Clin Immunol. 1985 Oct;76(4):628–636. doi: 10.1016/0091-6749(85)90786-9. [DOI] [PubMed] [Google Scholar]
  32. Kroegel C., Yukawa T., Dent G., Chanez P., Chung K. F., Barnes P. J. Platelet-activating factor induces eosinophil peroxidase release from purified human eosinophils. Immunology. 1988 Jul;64(3):559–561. [PMC free article] [PubMed] [Google Scholar]
  33. Laitinen L. A., Heino M., Laitinen A., Kava T., Haahtela T. Damage of the airway epithelium and bronchial reactivity in patients with asthma. Am Rev Respir Dis. 1985 Apr;131(4):599–606. doi: 10.1164/arrd.1985.131.4.599. [DOI] [PubMed] [Google Scholar]
  34. Lee T., Lenihan D. J., Malone B., Roddy L. L., Wasserman S. I. Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem. 1984 May 10;259(9):5526–5530. [PubMed] [Google Scholar]
  35. Lellouch-Tubiana A., Lefort J., Simon M. T., Pfister A., Vargaftig B. B. Eosinophil recruitment into guinea pig lungs after PAF-acether and allergen administration. Modulation by prostacyclin, platelet depletion, and selective antagonists. Am Rev Respir Dis. 1988 Apr;137(4):948–954. doi: 10.1164/ajrccm/137.4.948. [DOI] [PubMed] [Google Scholar]
  36. Lewis A. J., Dervinis A., Chang J. The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. Agents Actions. 1984 Dec;15(5-6):636–642. doi: 10.1007/BF01966785. [DOI] [PubMed] [Google Scholar]
  37. Metzger W. J., Zavala D., Richerson H. B., Moseley P., Iwamota P., Monick M., Sjoerdsma K., Hunninghake G. W. Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Description of the model and local airway inflammation. Am Rev Respir Dis. 1987 Feb;135(2):433–440. doi: 10.1164/arrd.1987.135.2.433. [DOI] [PubMed] [Google Scholar]
  38. O'Donnell S. R., Barnett C. J. Microvascular leakage to platelet activating factor in guinea-pig trachea and bronchi. Eur J Pharmacol. 1987 Jun 26;138(3):385–396. doi: 10.1016/0014-2999(87)90477-8. [DOI] [PubMed] [Google Scholar]
  39. Page C. P. The role of platelet-activating factor in asthma. J Allergy Clin Immunol. 1988 Jan;81(1):144–152. doi: 10.1016/0091-6749(88)90233-3. [DOI] [PubMed] [Google Scholar]
  40. Reed C. E. New therapeutic approaches in asthma. J Allergy Clin Immunol. 1986 Apr;77(4):537–543. doi: 10.1016/0091-6749(86)90342-8. [DOI] [PubMed] [Google Scholar]
  41. Retief F. P. South Africa's children. Lancet. 1984 Nov 3;2(8410):1042–1043. doi: 10.1016/s0140-6736(84)91142-5. [DOI] [PubMed] [Google Scholar]
  42. Roberts N. M., McCusker M., Chung K. F., Barnes P. J. Effect of a PAF antagonist, BN52063, on PAF-induced bronchoconstriction in normal subjects. Br J Clin Pharmacol. 1988 Jul;26(1):65–72. doi: 10.1111/j.1365-2125.1988.tb03365.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Roberts N. M., Page C. P., Chung K. F., Barnes P. J. Effect of a PAF antagonist, BN52063, on antigen-induced, acute, and late-onset cutaneous responses in atopic subjects. J Allergy Clin Immunol. 1988 Aug;82(2):236–241. doi: 10.1016/0091-6749(88)91005-6. [DOI] [PubMed] [Google Scholar]
  44. Robertson D. N., Coyle A. J., Rhoden K. J., Grandordy B., Page C. P., Barnes P. J. The effect of platelet-activating factor on histamine and muscarinic receptor function in guinea pig airways. Am Rev Respir Dis. 1988 Jun;137(6):1317–1322. doi: 10.1164/ajrccm/137.6.1317. [DOI] [PubMed] [Google Scholar]
  45. Roche W. R., Beasley R., Williams J. H., Holgate S. T. Subepithelial fibrosis in the bronchi of asthmatics. Lancet. 1989 Mar 11;1(8637):520–524. doi: 10.1016/s0140-6736(89)90067-6. [DOI] [PubMed] [Google Scholar]
  46. Shalit M., Valone F. H., Atkins P. C., Ratnoff W. D., Goetzl E. J., Zweiman B. Late appearance of phospholipid platelet-activating factor and leukotriene B4 in human skin after repeated antigen challenge. J Allergy Clin Immunol. 1989 Mar;83(3):691–696. doi: 10.1016/0091-6749(89)90084-5. [DOI] [PubMed] [Google Scholar]
  47. Snyder F. Chemical and biochemical aspects of platelet activating factor: a novel class of acetylated ether-linked choline-phospholipids. Med Res Rev. 1985 Jan-Mar;5(1):107–140. doi: 10.1002/med.2610050105. [DOI] [PubMed] [Google Scholar]
  48. Spina D., Coyle A. J., Page C. P. The role of platelet activating factor in allergic inflammation. Pulm Pharmacol. 1989;2(1):13–19. doi: 10.1016/s0952-0600(89)80004-3. [DOI] [PubMed] [Google Scholar]
  49. Taylor K. J., Luksza A. R. Peripheral blood eosinophil counts and bronchial responsiveness. Thorax. 1987 Jun;42(6):452–456. doi: 10.1136/thx.42.6.452. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Terashita Z., Tsushima S., Yoshioka Y., Nomura H., Inada Y., Nishikawa K. CV-3988 - a specific antagonist of platelet activating factor (PAF). Life Sci. 1983 Apr 25;32(17):1975–1982. doi: 10.1016/0024-3205(83)90049-8. [DOI] [PubMed] [Google Scholar]
  51. Vathenen A. S., Knox A. J., Higgins B. G., Britton J. R., Tattersfield A. E. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. 1988 Mar 12;1(8585):554–558. doi: 10.1016/s0140-6736(88)91352-9. [DOI] [PubMed] [Google Scholar]
  52. Wang J. M., Rambaldi A., Biondi A., Chen Z. G., Sanderson C. J., Mantovani A. Recombinant human interleukin 5 is a selective eosinophil chemoattractant. Eur J Immunol. 1989 Apr;19(4):701–705. doi: 10.1002/eji.1830190420. [DOI] [PubMed] [Google Scholar]
  53. Wardlaw A. J., Moqbel R., Cromwell O., Kay A. B. Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest. 1986 Dec;78(6):1701–1706. doi: 10.1172/JCI112765. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES